-
GSK Commits USD 800 Million to New State-of-the-Art Manufacturing Facility in Pennsylvania
•
GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced a significant investment in the United States with the establishment of a multi-purpose facility in Marietta, Pennsylvania. The company will invest USD 800 million to develop a state-of-the-art drug substance manufacturing facility and additional drug product manufacturing capabilities, creating…
-
ImmuneOnco Biopharmaceuticals Partners with Yangtze River Pharmaceutical to Boost Pipeline Development
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a biopharmaceutical company based in China, has entered into a strategic partnership with fellow Chinese firm Yangtze River Pharmaceutical (Group) Co., Ltd. This collaboration aims to strengthen and enhance the development of ImmuneOnco’s investigational pipeline programs. The partnership encompasses a wide range of…
-
LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS
•
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control over LM-302, an antibody drug conjugate (ADC) targeting Claudin 18.2, from US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY). LaNova had previously signed an agreement with Turning Point Therapeutics, Inc. (TPTX.US) in May 2022 to…
-
Zhuhai Beihai Biotech’s Beizary Receives FDA Clearance for Multiple Cancer Indications
•
Zhuhai Beihai Biotech Co., Ltd has announced that it has received marketing clearance from the US Food and Drug Administration (FDA) for its in-house developed drug, Beizary, a modified version of docetaxel, which is indicated for the treatment of various cancers including breast cancer, non-small cell lung cancer, head and…
-
BeiGene’s PD-1 Inhibitor Tevimbra Scores First US Prescription, Offers More Affordable Option
•
BeiGene Ltd, a leading China-based biotechnology company (NASDAQ: BGNE; HKG: 6160; SHA: 688235), has announced the first prescription of its programmed death-1 (PD-1) inhibitor, Tevimbra (tislelizumab), in the United States. This marks a significant milestone for the company as it expands its global reach. Tislelizumab received approval in the US…
-
RemeGen’s Telitacicept Receives Priority Review Status from China’s CDE for gMG Treatment
•
RemeGen (HKG: 9995), a China-based pharmaceutical company, has announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted another market filing for its drug telitacicept with priority review status. The filing seeks approval for the treatment of generalized myasthenia gravis (gMG), a serious…
-
China’s Pharmaceutical Trade Reaches USD 147.491 Billion in First Three Quarters, Export Growth Outpaces Imports
•
The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE) has released a summary of China’s health sector trade performance for the first nine months of this year. China’s global pharmaceutical product trade reached a total of USD 147.491 billion, with imports valued at USD…
-
RemeGen’s Taitaxipu Receives CDE Acceptance for New Indication Application in China
•
RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) has announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted a new indication application for its Claudin18.2-targeted antibody, Taitaxipu (Telitacicept), in combination with tislelizumab and chemotherapy as a first-line treatment for advanced gastric cancer. This…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis Novo Nordisk NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
